Shots:
The P-III (COMMANDS) study evaluating Reblozyl vs epoetin alfa in patients with anemia due to very low, low- or intermediate-risk (IPSS-R) MDS in patients who are RBC transfusion-dependent & were ESA naïve. The therapy is being developed & commercialized through global collaboration with Merck
The trial met its 1EPs i.e., clinical improvement in red blood cell transfusion independence (RBC-TI) with concurrent Hb increase. The safety results were consistent with the safety profile of Reblozyl prior reported in the (MEDALIST) study & no new safety signals were observed
The company will work with investigators to present detailed results at an upcoming medical meeting & discussed with health authorities
Ref: Businesswire | Image: BMS
